On the stock market since 2004, it operates in the world of health and science. It has 3,000 employees. Now — the numbers.
This is an established company with proven profits.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
No real growth (2% a year). Red columns mark years that ended in a loss.
The gap is $757.4M. In times of high interest rates, a gap like that can squeeze a company.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
The stock trades 45% below its peak. The market has trimmed its expectations for the company.
The average analyst price target is $58.00 — 46% above today’s price.
Over the last 3 years, sales grew only 1% a year on average. At this size, speeding back up is not easy.
The company’s market value is 52 times its annual profit. Even a small disappointment could hit the price hard.
On our five-subject report card, NUVA sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: NUVA is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.